SCHEMBL4718329

SCHEMBL4718329

Cc1cccnc1-c1cnnc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.51
METAP2 P50579 1/20 0.41
CNR2 P34972 1/20 0.40
TRPV1 Q8NER1 5/20 0.40
GRIA2 P42262 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
SMO Q99835 6/20 0.36
ABL1 P00519 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5918310 0.85 CNR2 (0.43) CYP2A6METAP2CNR2TRPV1GABRA1
SCHEMBL5918417 0.81 GABRG2 (0.36) CYP2A6CNR2GABRA1GABRG2GABRB3
SCHEMBL5918381 0.80 CYP11B2 (0.36) CYP11B2
SCHEMBL5918405 0.80 CYP2A6 (0.53) CYP2A6METAP2CNR2TRPV1GRIA2
SCHEMBL5918420 0.78 KCNA5 (0.33) TRPV1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5918467 0.78 RORB (0.41) TRPV1SMO
SCHEMBL27876851 0.77 CYP11B2 (0.43) CYP2A6METAP2CNR2TRPV1GABRA1
SCHEMBL5481966 0.77 TRPV1 (0.45) TRPV1
SCHEMBL5918319 0.77 CYP2A6 (0.47) CYP2A6METAP2CNR2TRPV1GRIA2
SCHEMBL5918403 0.77 CNR2 (0.44) METAP2CNR2TRPV1GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060154930-A1 Substituted amino heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-07-13 US disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1597261-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-11-23 EP disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004074290-A1 SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-09-02 WO disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154930-A1 Substituted amino heterocycles as vr-1 antagonists for treating pain OPRL1, OPRM1, OPRK1 CYP2A6 532/4885METAP2 3141/4885CNR2 26/4885
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 CYP2A6 293/4885METAP2 2243/4885CNR2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.